UY33392A - Lactamas sustituidas con piperidinilo como moduladores de gpr119 - Google Patents

Lactamas sustituidas con piperidinilo como moduladores de gpr119

Info

Publication number
UY33392A
UY33392A UY0001033392A UY33392A UY33392A UY 33392 A UY33392 A UY 33392A UY 0001033392 A UY0001033392 A UY 0001033392A UY 33392 A UY33392 A UY 33392A UY 33392 A UY33392 A UY 33392A
Authority
UY
Uruguay
Prior art keywords
gpr119
modulators
readers
piperidinyl
replaced
Prior art date
Application number
UY0001033392A
Other languages
English (en)
Inventor
Thomas Daniel Aicher
Josef Roland Bencsik
Steven Armen Boyd
Kevin Ronald Condroski
Bradford Jay
John P Fischer
Ronald Jay Hinklin
Scott Alan Pratt
Singh Ajay
Timothy M Turner
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of UY33392A publication Critical patent/UY33392A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Compuestos de la Fórmula I y sales farmacéuticamente de ellos, en donde X 1 , X2 , L, R3 , R4 ,R5 , R6 , R6a , R7 , R9 , R9a , y n tienen las definiciones que se dieron en la memoria descriptiva, son moduladores de GPR119 y son útiles en el tratamiento o la prevención de enfermedades tales como, en forma no taxativa, diabetes tipo 2, complicaciones diabéticas, síntomas de la diabetes, síndrome metabólico, obesidad, dislipidemia y condiciones relacionadas .
UY0001033392A 2010-05-17 2011-05-17 Lactamas sustituidas con piperidinilo como moduladores de gpr119 UY33392A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34546110P 2010-05-17 2010-05-17

Publications (1)

Publication Number Publication Date
UY33392A true UY33392A (es) 2012-11-30

Family

ID=44584599

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033392A UY33392A (es) 2010-05-17 2011-05-17 Lactamas sustituidas con piperidinilo como moduladores de gpr119

Country Status (20)

Country Link
US (1) US8754226B2 (es)
EP (1) EP2571864A1 (es)
JP (1) JP2013530947A (es)
KR (1) KR20130113948A (es)
CN (1) CN103080101A (es)
AR (1) AR081197A1 (es)
AU (1) AU2011256455A1 (es)
BR (1) BR112012029395A2 (es)
CA (1) CA2799779A1 (es)
CL (1) CL2012003211A1 (es)
CO (1) CO6670520A2 (es)
CR (1) CR20120642A (es)
IL (1) IL223092A0 (es)
MX (1) MX2012013465A (es)
RU (1) RU2012154308A (es)
SG (1) SG185615A1 (es)
TW (1) TW201141849A (es)
UY (1) UY33392A (es)
WO (1) WO2011146335A1 (es)
ZA (1) ZA201209605B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754226B2 (en) 2010-05-17 2014-06-17 Array Biopharma Inc. Piperidinyl-substituted lactams as GPR119 modulators
EP2718279B1 (en) 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Novel compounds as modulators of gpr-119
KR101415742B1 (ko) * 2011-12-21 2014-07-04 영남대학교 산학협력단 6―아미노피리딘―3―올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9499482B2 (en) 2012-09-05 2016-11-22 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
AR092924A1 (es) 2012-10-09 2015-05-06 Sanofi Sa Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CN105431435A (zh) * 2013-06-07 2016-03-23 拜耳制药股份公司 具有作为mps-1抑制剂的活性的取代的三唑并吡啶类
AR099936A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
RU2016143092A (ru) * 2014-04-04 2018-05-08 Санофи Замещенные соединения инданона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
JP6649279B2 (ja) 2015-01-19 2020-02-19 株式会社フジミインコーポレーテッド 変性コロイダルシリカおよびその製造方法、並びにこれを用いた研磨剤
TWI763621B (zh) * 2015-01-19 2022-05-11 日商福吉米股份有限公司 研磨用組成物之製造方法
EP3390399A1 (en) 2015-12-17 2018-10-24 Syngenta Participations AG Microbiocidal oxadiazole derivatives
EP3585775B1 (en) 2017-02-21 2022-04-06 Sanofi Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
EP4153589A1 (en) 2020-05-19 2023-03-29 Kallyope, Inc. Ampk activators
JP2023531020A (ja) 2020-06-22 2023-07-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト スルホン誘導体
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN114539073A (zh) * 2022-02-18 2022-05-27 郑州萃智医药科技有限公司 3-溴-2-氯-4,6-二氟苯胺的合成方法
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
WO2005061489A1 (en) 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
EP1732885A1 (en) 2004-02-23 2006-12-20 Trustees Of Tufts College Lactams as conformationally constrained peptidomimetic inhibitors
TW200610761A (en) 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
CN1997640A (zh) 2004-06-04 2007-07-11 艾尼纳制药公司 作为代谢调节剂的经取代芳基和杂芳基衍生物及其相关病症的预防和治疗
EP1817302A4 (en) * 2004-11-22 2009-07-01 Merck & Co Inc PIPERIDINYLPIPERIDIN-tachykinin receptor Antagonist
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20090264650A1 (en) * 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
US20090203676A1 (en) 2005-06-30 2009-08-13 Oscar Barba G-protein Coupled Receptor Agonists
US20100063081A1 (en) 2005-06-30 2010-03-11 Stuart Edward Bradly CPCR Agonists
US20080025795A1 (en) * 2006-07-28 2008-01-31 Cliff Purnell Methods, apparatus and system for drain tiles
US20080103123A1 (en) * 2006-08-30 2008-05-01 Biovitrum New compounds
JP2010513488A (ja) 2006-12-20 2010-04-30 メルク・シャープ・エンド・ドーム・コーポレイション ビピペリジニル化合物、その化合物を含有する組成物及び治療方法
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
US20110230507A1 (en) 2008-07-10 2011-09-22 Prosidion Limited Piperidine GPCR Agonists
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
CN107011330B (zh) * 2009-09-04 2020-07-03 比奥根Ma公司 布鲁顿酪氨酸激酶抑制剂
CN102918027A (zh) 2010-04-06 2013-02-06 艾尼纳制药公司 Gpr119受体调节剂和对与所述受体有关的障碍的治疗
US8754226B2 (en) 2010-05-17 2014-06-17 Array Biopharma Inc. Piperidinyl-substituted lactams as GPR119 modulators
RU2013117403A (ru) 2010-09-17 2014-10-27 Эррэй Биофарма Инк. Пиперидинил-замещенные лактамы как модуляторы gpr119
WO2013066869A1 (en) 2011-11-03 2013-05-10 Array Biopharma Inc. Piperidinyl-substituted lactams as gpr119 modulators
US20140309226A1 (en) 2011-11-16 2014-10-16 Array Biopharma Inc. Piperidinyl-substituted cyclic ureas as gpr119 modulators

Also Published As

Publication number Publication date
EP2571864A1 (en) 2013-03-27
RU2012154308A (ru) 2014-06-27
US20130158009A1 (en) 2013-06-20
WO2011146335A1 (en) 2011-11-24
US8754226B2 (en) 2014-06-17
CL2012003211A1 (es) 2013-04-26
AU2011256455A1 (en) 2013-01-10
MX2012013465A (es) 2013-12-02
TW201141849A (en) 2011-12-01
CA2799779A1 (en) 2011-11-24
ZA201209605B (en) 2014-05-28
BR112012029395A2 (pt) 2016-07-26
AR081197A1 (es) 2012-07-04
IL223092A0 (en) 2013-02-03
SG185615A1 (en) 2012-12-28
KR20130113948A (ko) 2013-10-16
CO6670520A2 (es) 2013-05-15
CN103080101A (zh) 2013-05-01
CR20120642A (es) 2013-03-11
JP2013530947A (ja) 2013-08-01

Similar Documents

Publication Publication Date Title
UY33392A (es) Lactamas sustituidas con piperidinilo como moduladores de gpr119
UY33614A (es) Lactamas sustituidas por piperidinilo como moduladores de gpr119
CU20140025A7 (es) Pirimidinas anilladas sustituidas
CR20110658A (es) Antagonistas de la trayectoria hedgehog de ftalazina desustituida
BR112013002957A2 (pt) composto de 1,4,5,6-tetrahidro-pirimidin-2-ilamina
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
AR077642A1 (es) Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
BR112012030482A2 (pt) tratamento de diabetes tipo 2
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
CO6491033A2 (es) 5-3,4-dicloro-fenil- n-(2-hidroxi-cicloheexil)- 6-(2,2,2-trifluoro etoxi)- nicotinamida y sales de la misma, como agentes que elevan el colesterol hdl
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
EA201590782A1 (ru) Оксирановые амины
FR2974364B1 (fr) Nouveaux derives amino-pyrroliniques, leur utilisation dans la prevention et/ou le traitement du syndrome metabolique
CO6700858A2 (es) Lactamas sustituidas por piperidinilo como moduladores de gpr119
UY34120A (es) Combinación sinérgica para el tratamiento de diabetes mellitus tipo 2
TH119594B (th) ลวดลายจาน
TH119596B (th) ลวดลายจาน
TH119593B (th) ลวดลายจาน
TH116511B (th) ลวดลายจาน
BR112015003815A2 (pt) métodos e composições para o tratamento de uma condição genética
TH119399B (th) ลวดลายแผ่นจักสาน

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200629